Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features.
Raman spectroscopy
machine learning
magnetic resonance imaging
multimodal imaging
prostate cancer
support vector machines
tissue optics
ultrasound imaging
Journal
Journal of biomedical optics
ISSN: 1560-2281
Titre abrégé: J Biomed Opt
Pays: United States
ID NLM: 9605853
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
23
03
2022
accepted:
12
08
2022
entrez:
10
9
2022
pubmed:
11
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
The diagnosis and treatment of prostate cancer (PCa) are limited by a lack of intraoperative information to accurately target tumors with needles for biopsy and brachytherapy. An innovative image-guidance technique using optical devices could improve the diagnostic yield of biopsy and efficacy of radiotherapy. To evaluate the performance of multimodal PCa detection using biomolecular features from in-situ Raman spectroscopy (RS) combined with image-based (radiomics) features from multiparametric magnetic resonance images (mpMRI). In a prospective pilot clinical study, 18 patients were recruited and underwent high-dose-rate brachytherapy. Multimodality image fusion (preoperative mpMRI with intraoperative transrectal ultrasound) combined with electromagnetic tracking was used to navigate an RS needle in the prostate prior to brachytherapy. This resulting dataset consisted of Raman spectra and co-located radiomics features from mpMRI. Feature selection was performed with the constraint that no more than 10 features were retained overall from a combination of inelastic scattering spectra and radiomics. These features were used to train support vector machine classifiers for PCa detection based on leave-one-patient-out cross-validation. RS along with biopsy samples were acquired from 47 sites along the insertion trajectory of the fiber-optics needle: 26 were confirmed as benign or grade group = 1, and 21 as grade group >1, according to histopathological reports. The combination of the fingerprint region of the RS and radiomics showed an accuracy of 83% (sensitivity = 81 % and a specificity = 85 % ), outperforming by more than 9% models trained with either spectroscopic or mpMRI data alone. An optimal number of features was identified between 6 and 8 features, which have good potential for discriminating grade group ≥1 / grade group <1 (accuracy = 87 % ) or grade group >1 / grade group ≤1 (accuracy = 91 % ). In-situ Raman spectroscopy combined with mpMRI radiomics features can lead to highly accurate PCa detection for improved in-vivo targeting of biopsy sample collection and radiotherapy seed placement.
Identifiants
pubmed: 36085571
pii: JBO-220064GR
doi: 10.1117/1.JBO.27.9.095004
pmc: PMC9459023
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Appl Clin Med Phys. 2021 Aug;22(8):284-294
pubmed: 34318581
Arch Pathol Lab Med. 2019 May;143(5):550-564
pubmed: 30865487
Eur Urol. 2020 Apr;77(4):481-490
pubmed: 31791623
BJU Int. 2018 Aug;122(2):326-336
pubmed: 29542855
Radiother Oncol. 2022 Jan;166:154-161
pubmed: 34861267
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:270-275
pubmed: 28384603
J Biomed Opt. 2009 Sep-Oct;14(5):054023
pubmed: 19895125
J Magn Reson Imaging. 2019 Mar;49(3):875-884
pubmed: 30230108
J Biophotonics. 2015 Jul;8(7):527-45
pubmed: 25220508
J Biophotonics. 2018 Jun;11(6):e201700288
pubmed: 29360199
Analyst. 2017 Aug 21;142(17):3025-3047
pubmed: 28726868
Biomed Opt Express. 2018 Aug 15;9(9):4294-4305
pubmed: 30615702
Brachytherapy. 2018 Mar - Apr;17(2):283-290
pubmed: 29331575
Med Phys. 2014 May;41(5):050901
pubmed: 24784365
IEEE Trans Med Imaging. 2014 Aug;33(8):1702-25
pubmed: 24816547
J Biophotonics. 2022 Jan;15(1):e202100212
pubmed: 34669263
Urol Clin North Am. 2014 May;41(2):299-313
pubmed: 24725491
J Biophotonics. 2018 Nov;11(11):e201800055
pubmed: 30079507
J Biomed Opt. 2018 Jun;23(7):1-23
pubmed: 29956506
Asian J Androl. 2014 Jul-Aug;16(4):522-9
pubmed: 24589455
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Transl Cancer Res. 2016 Aug;5(4):432-447
pubmed: 29188191
J Labelled Comp Radiopharm. 2018 May 2;:
pubmed: 29722070
J Am Chem Soc. 2021 Aug 11;143(31):12253-12260
pubmed: 34320323
Br J Cancer. 2003 Jul 7;89(1):106-8
pubmed: 12838309
Lasers Med Sci. 2020 Oct;35(8):1791-1799
pubmed: 32285292
Sci Rep. 2018 Jan 29;8(1):1792
pubmed: 29379121
Brachytherapy. 2021 Nov-Dec;20(6):1296-1304
pubmed: 34272132
J Biophotonics. 2022 Jun;15(6):e202100354
pubmed: 35233990
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Exp Dermatol. 2015 Oct;24(10):767-72
pubmed: 26010742
J Urol. 2016 Jul;196(1):62-7
pubmed: 26880408
Sci Rep. 2019 Jul 1;9(1):9441
pubmed: 31263116
Biomed Opt Express. 2015 Jun 08;6(7):2380-97
pubmed: 26203368
Ther Adv Urol. 2019 Aug 28;11:1756287219870074
pubmed: 31489033
Int J Comput Assist Radiol Surg. 2020 May;15(5):867-876
pubmed: 32227280
Brachytherapy. 2014 Nov-Dec;13(6):640-50
pubmed: 24929641
Cancers (Basel). 2021 Apr 19;13(8):
pubmed: 33921713
Eur J Radiol. 2019 Jun;115:16-21
pubmed: 31084754
J Biomed Opt. 2019 Feb;24(2):1-10
pubmed: 30767440
PLoS Med. 2020 Aug 14;17(8):e1003281
pubmed: 32797086
J Biomed Opt. 2022 Sep;27(9):
pubmed: 36045491
J Healthc Eng. 2018 Jun 7;2018:8619342
pubmed: 29977484
Expert Rev Med Devices. 2018 Jan;15(1):71-79
pubmed: 29251165